Advanced Accelerator Applications S.A. announced that its product NETSPOT (gallium Ga-68 dotatate) has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology version 1.2017 update for the evaluation of neuroendocrine tumors (NETs) NETSPOT, a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor-positive NETs, was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2016, 23 months from the first pre-Investigational New Drug meeting with the agency.
AAA and its radiopharmacy partners around the U.S. are now delivering 400 doses of NETSPOT per month. This advance in imaging capability provides treating physicians with enormous insights, enabling better directed surgeries and enhanced decision making regarding different therapeutic options. Ultimately, the use of NETSPOT will lead to improved outcomes for patients.
For more information: www.adacap.com